Opinion on influence of erythropoietin on quality of life and survival in patients with advanced non-small cell lung cancer;Ocena wpływu erytropoetyny na jakość i czas przeżycia chorych na zaawansowanego niedrobnokomórkowego raka płuc

Wspolczesna Onkologia

Volumn 11, Issue 1, 2007, Pages 37-40

  Zemełka, Tomasz ^a   Rolski, Janusz ^a   Ziobro, Marek ^a   Michalczyk, Agnieszka ^a  

^a INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

Anaemia; Erythropoietin; Lung cancer

Indexed keywords

CARBOPLATIN; CISPLATIN; ERYTHROPOIETIN; ETOPOSIDE; HEMOGLOBIN; NAVELBINE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ERYTHROCYTE TRANSFUSION; FATIGUE; FEMALE; HEMOGLOBIN DETERMINATION; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; QUALITY OF LIFE; REMISSION; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE;

EID: 34147193891     PISSN: 14282526     EISSN: 14282526     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Krzakowski M. Niedrobnokomórkowy rak płuca - postȩpy w leczeniu. Nowa Medycyna 2001; 113: 5-6.
2. Cortes-Funes H. New treatment approaches for lung cancer and impact on survival. Semin Oncol 2002; 29 (3 supl. 8): 26-9.
3. McKenna RJ Jr., Movsas B, Shin DM, Khuri FR. Non-small-cell lung cancer, mesothelioma, and thymoma. W: Pazdur R, Coia LR, Hoskins WJ, et al. [eds]. Cancer Management: A Multidisciplinary Approach. 8th ed. F. A. Davis Company, Philadelphia, PA 2004: 123-64.
4. Bokemeyer C, Aapro MS, Courdi A, Foubert J, Link H, Osterborg A, Repetto L, Soubeyran P. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur J Cancer 2004; 40: 2201-16.
5. Van Belle SJ, Cocquyt V. Impact of haemoglobin levels on the outcome of cancers treated with chemotherapy. Crit Rev Oncol Hematol 2003; 47: 1-11.
6. ten Bokkel Huinink WW, de Swart CA, van Toorn DW, et al. Controlled multicentre study of the influence of subcutaneous recombinant human erythropoietin on anaemia and transfusion dependency in patients with ovarian carcinoma treated with platinum-based chemotherapy. Med Oncol 1998; 15: 174-82.
7. Leyland-Jones B, on behalf of the BEST investigators and study group. Breast Cancer trial with erythropoietin terminated unexpectedly. Lancet Oncology 2003; 4459-460.
8. Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003; 362: 1255-60.
9. Littlewood TJ, Nortier J, Rapoport B, et al.; Epoetin Alfa Study Group. Epoetin alfa corrects anemia and improves quality of life in patients with hematologic malignancies receiving non-platinum chemotherapy. Hematol Oncol 2003; 21:169-80.
10. Janinis J, Dafni U, Aravantinos G, et al. Quality of life (QoL) outcome of epoietin-alfa (EPO-A) in anemic cancer patients undergoing platinum or non-platinum-based chemotherapy: A randomized study conducted by the Hellenic Cooperative Oncology Group. Proc Am Soc Clin Oncol 2003; 22: 789. Abstract 3172.